Osteoporosis Drugs Market

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.

Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.

Osteoporosis Drugs Market contains market size and forecasts of Osteoporosis Drugs in global, including the following market information:

Global Osteoporosis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Osteoporosis Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Osteoporosis Drugs companies in 2021 (%)

The global Osteoporosis Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antiresorptive Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Osteoporosis Drugs include Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Osteoporosis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Osteoporosis Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Osteoporosis Drugs Market Segment Percentages, by Type, 2021 (%)

Antiresorptive Drugs

Anabolic Drugs

Global Osteoporosis Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Osteoporosis Drugs Market Segment Percentages, by Application, 2021 (%)

Female

Male

Global Osteoporosis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Osteoporosis Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Osteoporosis Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Osteoporosis Drugs revenues share in global market, 2021 (%)

Key companies Osteoporosis Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Osteoporosis Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Eli Lilly

Novartis

Pfizer

Amgen

Merck

Novo nordisk

Actavis

Roche